Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1036)	5/2/2000 1:43:00 PM
From: scaram(o)uche	Respond to of 52153

>> Anyone heard a "plantibody" update lately? This seems like one way this chain might eventually break, but looks like it's still a good few years off. << I've got a small private placement in EPIcyte. Going well, from what I hear.

To: Biomaven who wrote (1036)	5/2/2000 4:57:00 PM
From: dalroi	Read Replies (1) \| Respond to of 52153

Peter concerning gztc and the goats seems pharming on the easdaq has the same technology competition ? cheers Stefaan

To: Biomaven who wrote (1036)	5/2/2000 5:32:00 PM
From: dalroi	Respond to of 52153

addition and further parking :-) In January Pharming was issued a third US patent on transgenic cattle, which broadly covers the production of recombinant proteins in the milk of transgenic cattle. Also in January a patent on nuclear transfer technology was issued to Pharming's partner Infigen, Inc., with claims covering both the use of primordial germ line derived cells (PGCs), as well as the use of somatic cells in Infigen's specific NT and cell culture procedures. Pharming is exclusively licensed under this patent for the production of pharmaceutical proteins in milk. In February, an Opposition Division of the European Patent Office (EPO) revoked one of Pharming's European patents covering methods for producing transgenic cattle. This Division's decision ends only the first round of the opposition procedure and Pharming can and will appeal with the EPO's higher instance, the Boards of Appeal. Filing of the appeal will restore Pharming's patent into force. The European Opposition does not affect Pharming's US patents on transgenic cattle. Pharming's US patents not only protect the use of transgenic cattle in the USA but also protect against import of products from transgenic cattle produced outside the USA. At present, Pharming's IP portfolio comprises 30 patents worldwide